Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Tarsus Pharmaceuticals, Inc.

Tarsus (NASDAQ:TARS) is a biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care.

Armentum Partners

Horowitz Group

Vivo Capital

Aperture Venture Partners

Visionary Venture Fund

Flying L Partners

Frazier Healthcare Partners

The first and only FDA-approved treatment for Demodex blepharitis (DB) is now available! We’re delighted to introduce this new therapeutic to the eye care community and thrilled at its potential to help many patients living with this disease.

We are so appreciative of our superstar Tarsus team and the many partners who worked diligently to make this important milestone happen. 

Read the full press release here: https://lnkd.in/eEQW3SEv

🌺 Aloha from the Hawaiian Eye & Retina 2024 Meeting! 

We love kicking off the New Year by attending this important and engaging meeting! This year, we had the privilege of connecting with leading experts in eye care across a variety of different platforms to share experiences about Demodex blepharitis and eyelid health. We appreciate the unique perspectives and compelling discussion and look forward to continuing the dialogue as we move further into 2024. 

Today, we commemorate the incredible life and impact of Dr. Martin Luther King Jr.

His unwavering dedication to justice, equality, and unity continues to inspire us. Dr. King had a vision for a brighter, more inclusive future, and we strive to honor that vision in everything we do at Tarsus.

This #MLKDay, we encourage our Tarsans to volunteer in their communities and reflect on Dr. King's commitments to peace, service, and education.

The Tarsus crew celebrated the holidays and rang in the New Year traveling, relaxing and spending time with loved ones!

We prioritize the health and well-being of our Tarsans and look forward to this important recharge break at the end of each year. Swipe through to see some highlights of our winter wellness week.

Discover more about the values that shape our culture: https://lnkd.in/eGeFU8_E

As we bid farewell to 2023, we’d like to reflect on what an incredible year it’s been.

2023 was a milestone year – we received FDA approval for the first and only treatment for Demodex blepharitis and just a few weeks into launch, we are well on our way to helping millions of potential patients. We experienced tremendous growth as an organization, more than doubling in size, and we were recognized by numerous independent companies as a great place to work.

We are grateful to our investigators, eye care provider partners, patients and our passionate team of Tarsans who helped us get to where we are today.

We are inspired and motivated to start 2024 and continue to deliver on our vision to make a meaningful difference in eye care and to the patients we serve. We wish everyone a happy and healthy holiday season.

See here for XDEMVY prescribing info: https://bit.ly/3Rrf4YB

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover				0.32 -	0.11 64.46%	0.07 42.16%
cash conversion cycle				-1.53K -	-1.92K 25.59%	-3.08K 60.47%
cash per share	0.55 -	24.53 4,363.07%	27.09 10.43%	8.36 69.14%	8.82 5.45%	7.74 12.19%
company equity multiplier	-1.76 -	-9.71 450.40%	1.04 110.67%	1.07 3.56%	1.18 10.08%	1.35 14.41%
days of inventory outstanding					1.82K -	711.90 60.89%
days of payables outstanding				1.53K -	3.79K 148.07%	4.16K 9.79%
days of sales outstanding				0.59 -	50.64 8,500.61%	370.59 631.74%
dividend yield
ebit per revenue				-0.21 -	-2.43 1,039.50%	-8.21 237.78%
ebt per ebit	0.98 -	1.09 11.27%	0.99 8.59%	1.13 14.08%	0.99 12.60%	0.95 4.13%
effective tax rate	-0.00 -	-0.00 71.77%	-0.00 82.58%	-0.00 10,606.87%	0.00 101.61%
enterprise value multiple	-63.63 -	2.33 103.66%	-3.32 242.31%	-27.70 734.88%	-5.23 81.11%	-2.82 46.04%
fixed asset turnover				31.18 -	16.85 45.95%	5.21 69.08%
free cash flow per share	-0.28 -	-1.63 486.47%	-3.48 113.61%	0.15 104.42%	-2.01 1,407.90%	-4.19 108.04%
gross profit margin				0.96 -	0.96 0.06%	0.91 5.64%
interest coverage			-143.61 -		-28.52 -	-42.78 50.03%
inventory turnover					0.20 -	0.51 155.67%
long term debt to capitalization		-0.02 -	0.00 119.47%	0.00 6.06%	0.09 2,517.71%	0.13 43.65%
net income per ebt	1.00 -	1.00 0.05%	1.00 0.02%	1.00 0.40%	1.00 0.40%	1 0.01%
net profit margin				-0.24 -	-2.41 891.96%	-7.79 223.84%
operating cash flow per share	-0.28 -	-1.55 463.11%	-3.41 119.06%	0.18 105.35%	-1.99 1,192.14%	-4.00 100.79%
operating cycle				0.59 -	1.87K 317,601.30%	1.08K 42.14%
operating profit margin				-0.21 -	-2.43 1,039.50%	-8.21 237.78%
payables turnover				0.24 -	0.10 59.69%	0.09 8.92%
pretax profit margin				-0.24 -	-2.41 895.98%	-7.79 223.82%
price fair value	-65.13 -	-8.10 87.57%	1.55 119.09%	2.77 79.45%	1.87 32.54%	3.02 61.44%
receivables turnover				619.86 -	7.21 98.84%	0.98 86.33%
return on assets	-0.55 -	-0.08 85.50%	-0.16 94.68%	-0.08 50.43%	-0.27 252.58%	-0.51 87.32%
return on capital employed	-0.61 -	-0.07 87.76%	-0.16 116.81%	-0.07 55.20%	-0.30 306.57%	-0.62 111.50%
return on equity	0.97 -	0.78 20.17%	-0.16 120.77%	-0.08 48.66%	-0.32 288.13%	-0.69 114.32%
total debt to capitalization		-0.03 -	0.00 117.74%	0.01 125.11%	0.09 743.55%	0.13 40.59%

COM:TARSUSRX

Tarsus Pharmaceuticals, Inc.

Last Close

46.40

22/11 21:00

Market Cap

1.07B

Beta: -

Volume Today

589.21K

Avg: -

Preview